A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
出版年份 2015 全文链接
标题
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
作者
关键词
Overall Survival, Bevacizumab, Cetuximab, Febrile Neutropenia, BRAF Mutation
出版物
Targeted Oncology
Volume 11, Issue 3, Pages 293-308
出版商
Springer Nature
发表日期
2015-12-19
DOI
10.1007/s11523-015-0400-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
- (2015) Alexander Stein et al. BRITISH JOURNAL OF CANCER
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Surgical Management of Hepatic Metastases of Colorectal Cancer
- (2015) J. Joshua Smith et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
- (2015) R. D. Nipp et al. ONCOLOGIST
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- The efficacy and safety of probiotics in people with cancer: a systematic review
- (2014) M. G. Redman et al. ANNALS OF ONCOLOGY
- Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
- (2014) Gunnar Folprecht et al. BMC CANCER
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- (2014) Rajesh V. Lalla et al. CANCER
- Guidance on the management of diarrhoea during cancer chemotherapy
- (2014) Jervoise Andreyev et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use
- (2014) Gisoo Barnes et al. Cancer Medicine
- FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
- (2013) L. Fornaro et al. ANNALS OF ONCOLOGY
- A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial
- (2013) Marc Ychou et al. ANNALS OF SURGICAL ONCOLOGY
- Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
- (2013) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Perioperative chemotherapy for resectable colorectal liver metastases: Where now?
- (2013) R.P. Jones et al. EJSO
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study
- (2013) Mohamed Hebbar et al. JOURNAL OF CHEMOTHERAPY
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases
- (2013) Le-Chi Ye et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
- (2012) Alexander Stein et al. BMC CANCER
- A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
- (2012) Z Saridaki et al. BRITISH JOURNAL OF CANCER
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
- (2012) Rachel J. Gibson et al. SUPPORTIVE CARE IN CANCER
- A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril
- (2012) Marion Eberlin et al. Frontiers in Pharmacology
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- Evidence Supporting the use of Probiotics for the Prevention and Treatment of Chemotherapy-Induced Intestinal Mucositis
- (2011) Luca D. Prisciandaro et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2011) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
- (2011) E. Assenat et al. ONCOLOGIST
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
- (2010) F. Roila et al. ANNALS OF ONCOLOGY
- Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
- (2010) C Garufi et al. BRITISH JOURNAL OF CANCER
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- (2010) Gianluca Masi et al. LANCET ONCOLOGY
- Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
- (2010) Matti Aapro et al. SUPPORTIVE CARE IN CANCER
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
- (2009) Cathy Eng Nature Reviews Clinical Oncology
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
- (2008) Brigit Gruenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases
- (2007) Srinevas K. Reddy et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More